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Summary Patients with refractory metastatic renal cell carcinoma (RCC) were enrolled in a phase 11 study with teniposide (VM26) and
cyclosporin A (CSA) to investigate (1) the effect of CSA on the response rate to VM26; and (2) the effect of CSA on the pharmacokinetics and
pharmacodynamics of VM26. Sixteen patients initially received VM26 alone (200 mg m-2 day-' i.v.). No objective responses were observed
and all patients crossed over to receive at least an additional two courses (range 2-5) of VM26 plus CSA (5 mg kg-' 2h-1 followed by 30 mg
kg-' 48h-1 i.v.). At the end of the 2-h loading dose of CSA, whole-blood CSA levels ranged from 2250 to 3830 ng ml-', whereas at the end of
the 48-h CSA infusion, CSA ranged from 1830 to 4501 ng ml-'. CSA significantly (P<0.01) increased the area underthe curve (AUC) of VM26.
The variation in the paired AUC of VM26 was 50%. Terminal half-life of VM26 was significantly (P<0.01) increased (1.72-fold) after CSA
administration, whereas the systemic clearance of VM26 was decreased by 1.4-fold (P<0.01). The nadir neutrophil count after VM26 plus
CSA (median 700 RI-1, range <100 to 2860 ,ul-1) was lower than after VM26 alone (median 1900 lal', range 200 to 6000 RI-1). Increased
haematological toxicity after CSA could be explained by the increase in the VM26 AUC and by inhibition of P-glycoprotein (P-gp) activity in
haematopoietic precursor cells. Bilirubin concentrations in the serum were increased after VM26 plus CSA compared with VM26 alone
(P<0.01). Among the 15 patients evaluable for response, one had a minor response, eight had stable disease, and six had progressive
disease. In conclusion, the dose of CSA we used achieved plasma concentrations within the effective range for P-gp inhibition. CSA affected
both the pharmacokinetics and pharmacodynamics of VM26 in the patients, principally by increasing the plasma concentrations of the
antineoplastic drug and VM26 haemopoietic toxicity.
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Renal cell carcinomas (RCCs) are poorly responsive to chemo-
therapy, the overall response rate being around 10%. For this
reason, new approaches are highly recommended after a first-line
treatment, usually interleukin 2 based (Yagoda et al, 1995). Over-
expression of the P-glycoprotein (P-gp) and complete unrespon-
sivity of RCCs to the broad spectrum of drugs included in the
multidrug-resistant (MDR) phenotype have led to the supposition
that P-gp activity could be detrimental to the success of
chemotherapy in these neoplasms (Fojo et al, 1987). P-gp deter-
mines reduced intracellular drug accumulation and/or altered
intracellular drug compartmentation, preventing drugs from
reaching the intracellular target site (Skovsgaard, 1978,
Schuurhuis et al, 1989). Several classes of agents have been
demonstrated to overcome MDR in experimental tumour systems
(Ford and Hait, 1990). These chemicals are thought to bind to
P-gp, to competitively inhibit the ATP-dependent membrane
pump, and thus to increase the intracellular concentration of the
cytotoxic agent or to determine intracellular drug redistribution at
the target site (Schuurhuis et al, 1989; Boiocchi and Toffoli, 1992).
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Although many chemosensitizers have been used successfully
in vitro in MDR cell lines, their potential therapeutic role in the
clinical setting remains an intriguing issue. MDR modulators
increase the cytotoxic effect of antineoplastic drugs only in a
restricted group of human haematologic neoplasms, whereas in
most solid tumours reversal treatment is generally ineffective and
can be associated with an increased toxicity in the normal tissue
expressing P-gp (Lehnert, 1993; Raderer and Scheithauer, 1993).
It has been suggested that an intrinsic characteristic of P-gp
inhibitors could interfere with the clearance of cytotoxic agents
through competition for efflux pumps involved in hepatic drug
clearance and biliary or renal excretion. This could determine
alteration in the pharmacokinetics and pharmacodynamics of the
cytotoxic agents (Lum et al, 1992; Wilson et al, 1995).
Cyclosporin A (CSA) is an effective inhibitor of P-gp activity
and has been demonstrated to modulate MDR in in vitro experi-
mental models, but its efficacy in vivo, especially in human solid
tumours, needs further clarification (Rodenburg et al, 1991;
Verweij et al, 1991; Twentyman, 1992; Yahanda et al, 1992;
Fridborg et al, 1994; Warner et al, 1995). Moreover, during degra-
dation of CSA, the metabolites arising from the parental
compound reach high levels in the serum (Maurer and Lemaire,
1986), and it is not clear whether these metabolites maintain the
reversal activity of the parental compound, like other metabolites
of reversal agents, such as verapamil (Toffoli et al, 1995).
In this study, we analysed the efficacy of CSA as an MDR
modulator in patients with metastatic renal cell carcinoma treated
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with teniposide (VM26), an antineoplastic drug involved in
MDR (Tew et al, 1993), and investigated the effect of CSA on the
pharmacokinetics and pharmacodynamics ofVM26 in the patients.
MATERIALS AND METHODS
Patient selection
The criteria of eligibility were: diagnosis of metastatic RCC in
progression after standard treatment, presence of evaluable
lesions, WHO performance status < 2, life expectancy > 3 months,
renal and hepatic tests < 1.5 of normal value (n.v.), absolute
neutrophil count (ANC) > 2000 ,ul-', platelets > 100 000 gl-',
absence of symptomatic CNS metastases and/or other diseases
requiring drugs known to be nephrotoxic or affecting CSA metab-
olism. The study was approved by the local ethics committee and
informed consent was obtained from all patients.
Treatment protocol
The patients received the first course of VM26 (Vumon; Bristol
Myers, Rome, Italy) at the dosage of200 mg m-2 day-' i.v. every 3
weeks. The second cycle (same dosage) was administered in the
event ofresponse or stable disease, if no toxicity was documented.
In the event of grade 4 toxicity the dose was reduced by 25%.
Patients with tumour progression or stable disease were treated
with the combination of VM26 and CSA (Sandimmun; Sandoz,
Milan, Italy). CSA (5 mg kg-') was administered in the event of
early progression or stable disease after the second cycle as an i.v.
loading dose over a 2-h period (-2 to 0 h of the protocol) followed
by i.v. continuous infusion for 48h (15 mg kg-' day-') (0 and 48h
of the protocol) together with VM26 (0-24h). The patients were
clinically evaluated according to the usual phase II trials criteria
(WHO), and blood tests were performed weekly.
Sample collection
VM26 and CSA pharmacokinetic analyses were performed during
the first cycle of VM26 alone and the first cycle of VM26 plus
CSA. To determine the VM26 level, 5-ml blood samples were
drawn from peripheral vein and collected in heparinized glass
tubes before treatment at 0 h (i.e. immediately before the begin-
ning of i.v. infusion of VM26) and at 1,6, 12, 18, 24,24.5,25,26,
28, 32, 36, 48 and 60h. Plasma samples, which were separated
aftercentrifugation at 1000g for 10 min, were kept frozen at- 20'C
until analysis. Urine samples were collected before, during and
after VM26 treatment. Each 12-h sample from well-stirred urine
was stored and kept frozen at -20°C until analysis. To determine
whole-blood CSA levels, blood samples were collected in
heparinized polypropylene tubes at -2, 0, 6, 12, 36, 48, 60 and
72 h. These samples were frozen at -70°C until analysis.
Drug assays
The method used to determine VM26 in plasma samples was that
described by Evans et al (1982). Briefly, 1 ml of plasma or urine
was extracted with 8 ml ofchloroform containing VP16 (100 gl of
a 200-,ug ml solution) as internal standard. After 20-min shaking
at +4°C, samples were centrifuged at 1500 g for 20 min at +4°C.
The organic phase was dried under vacuum and then redissolved
with 200 gl of methanol; 50 ,ul of this solution as injected into an
LKB-Pharmacia (Cambridge, UK) high-performance liquid chro-
matography (HPLC) system equipped with an absorbance detector
set at 254 nm.
Separation was achieved using an isocratic solvent system of
water-acetonitrile-acetic acid (64:35:1) at a flow of 1 ml min-,
using a 300 x 3.9-mm long ,uBondapak phenyl column (Waters,
New York, NY, USA). Peak areas were quantitated with an LKB
integrator. The relationship between peak area of VM26 and
Table 1 Patient characteristics
Patient Age Sex Performance Previous treatment Metastatic site VM26 Response VM26+CSA Response Duration
status (no. of cycles) (VM26) (no. of cycles) (VM26+CSA) (months)
1 56 M 1 IL-2 Liver, bone, lung 2 SD 2 SD 2
2 60 M 2 MAP Kidney (primary site), 2 PD 4 SD 5
lymph node
3 71 F 2 IL-2-lFN Liver, lung 2 PD 4 SD 3
4 63 M 1 IL-2-IFN-FUDR Lung, lymph node 2 PD 4 SD 4
5 52 M 1 IL-2-IFN, FUDR, VBL Lung 2 SD 5 SD 4
6 75 M 1 High-dose IL-2 Lung 2 SD 3 SD(MR) 14
7 61 M 3 IL-2-IFN Lung, thorax 2 PD 1 PD
8 44 F 2 IL-2-IFN Liver, bone 2 PD 2 PD
9 53 M 1 IL-2-IFN Lung, mediastinum, 2 PD 2 SD 2
subcutaneous, bone
10 50 M 2 IL-2-IFN-5-FU, RT Oral cavity, kidney, 1 NV 2 PD
heart, lymph node
11 75 M 2 RT Lung,bone 1 NV 2 NV
12 70 F 1 RT, FUDR, IL-2-IFN Mediastinum, bone 1 NV 2 SD 4
13 52 F 1 VBL-IFN Lymph node, subcutaneous 1 NV 3 PD
14 56 F 1 IL-2-IFN-MmDox Lung 1 NV 2 PD
15 57 F 1 IL-2, 5-FU Lung, lymph node, kidney, 1 NV 2 PD
neck, mediastinum, abdomen
16 71 F 3 IL-2-5-FU, Bone, kidney, 1 NV 2 PD
IL-2-IFN, RT lymph node
SD, stable disease; PD, progressive disease; MR, minimal response; NV, not valuable; IL-2, interleukin 2; MAP, medroxyprogesterone acetate; IFN, ax
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concentration was fairly linear in the range of concentrations of
interest. To calculate the concentrations of VM26, the internal
standard method was adopted.
The sensitivity ofthe method was 0.25,g ml-'; the intra-day and
interday imprecision was within 15%; the inaccuracy ofthe method
ranged from 5% to 15% at different concentrations (20-1 ,ug ml-').
Whole-blood levels ofCSA and CSA metabolites were analysed
by a non-specific fluorescence polarization immunoassay method
using the CSA monoclonal TDx and the CSA plus metabolite
polyclonal TDx (Abbott Laboratories, North Chicago, IL, USA)
with a sensitivity of 40 ng ml' and an interassay coefficient of
variation less than 10%. Cross-reactivity of CSA plus metabolite
polyclonal TDx was: 103.5%, 13.7%, 19.0%, 66.9%, 79.8%,
62.6%, 0.0%, 60.5%, 27.0% and 100% for metabolites M17, M8,
Ml, M21, M18, M25, M26, M203-218, MUNDF1 and CSA
respectively.
Pharmacokinetic analyses
To define the plasma concentration-time function and to estimate
pharmacokinetic parameters ofVM26 for each patient, a compart-
mental model was adopted. Drug infusion and non-saturable elim-
ination processes were considered zero-order and first-order
processes respectively.
Estimates of pharmacokinetic parameters [apparent volume of
distribution (V); elimination half-life (t1,2p); systemic clearance
(CI); maximum drug concentration (Cmax); and area under curve
(AUC)] of VM26 and the numerical validation of the model were
obtained by PCNONLIN 4.0, a non-linear regression program.
The terminal elimination rate constant (K) was estimated by
unweighted least square linear regression analysis of the elimina-
tion phase ofthe VM26 plasma concentration-time curve.
The fraction of drug excreted unmodified in the urine (fu) was
calculated as the ratio between the cumulative amount of drug
found in the urine and the dose administered by i.v. infusion. AUC
of CSA was calculated by the trapezoidal rule to the last experi-
mental point. A complete sampling schedule was performed
during the first course of VM26 alone and of VM26 plus CSA
-T 5000
c' 4000
CD 3000 C.)
C 900- r= -0.15
< ~P= NS
co 600;
0 40 80 120
a CSA AUC
T
Oh 48h If
72 h
Figure 1 Whole-blood plasma concentrations of CSA (E) and CSA plus
metabolites (U) at the end of a 2-h CSA loading dose (Oh), at the end of
CSA continuous infusion (48h) and 24h after the end of CSA infusion (72h).
Bars, s.d. (-) The excess between CSA plus CSA metabolites and CSA
alone. Inset: scatter diagram of VM26 AUC vsCSA AUC (rg h 1-1); r,
correlation factor, and P, significance
for each patient. Thus, paired concentration-time courses and
pharmacokinetic parameters were available.
The t-test for paired data was performed for each parameter to
compare the kinetics of VM26 administered alone and with CSA.
A search for correlation between kinetic and dynamic parameters
was performed by linear and non-linear least square regression.
The significance of the coefficients of the correlation found was
determined by the table reported by Taylor (1990).
RESULTS
Patient characteristics
Sixteen patients entered the study and received VM26 and CSA
according to the protocol when they had stable or progressive
disease over treatment on VM26 alone. Patient characteristics are
listed in Table 1. The median age was 60 years (range 44-75) and
the median performance status was 1 (two patients with PS = 3
were treated in spite of a protocol violation). The patients had
previously received a median of one therapeutic regimen (range
1-5), not including VM26.
CSA plasma level
CSA levels ofthe 16 patients entered in the study are illustrated in
Figure 1. At the end of the 2-h loading dose of CSA (0 h of the
protocol), whole-blood CSA levels ranged from 2250 to 3830 ng
ml-' (median 2955 ng ml-), whereas at the end of the 48-h CSA
infusion, plasma levels ofCSA ranged from 1830 to 4501 ng ml-')
(median 2415 ng ml-'). The levels of CSA ranged from 635 to
870 ng ml-' (median 680 ng ml-') 24 h after the end ofthe infusion
(72 h of the protocol). In Figure 1 the cumulative level of CSA
plus some CSA metabolites is also shown as determined by the
TDx cyclosporin and metabolite Abbot kits (see Materials and
methods). Even if the comparison between the determinations
performed with the two kits could be inaccurate, the values
obtained by subtracting the values obtained by the polyclonal kit
from those obtained by the monoclonal kit indicate thatcumulative
CSA metabolite levels were similar to the CSA levels at the end of
CSA infusion (48 h of the protocol) and were higher than CSA
levels 24 h after the end of CSA infusion (72 h of the protocol)
(Figure 1).
VM26 pharmacokinetics
Pharmacokinetics of VM26 administered alone and co-adminis-
tered with CSA was evaluated in all 16 patients by serial blood
sampling during the first course oftreatment.
We found that CSA had a significant effect (P<0.01) on the
AUC of VM26. In the presence of CSA, the AUC of VM26 was
nearly 1.5-fold higher (by the paired data, Table 2). In the cycles
with VM26 alone, the median value of VM26 in individual
patients ranged from 168.4 to 791 mg 1-lh (median 290.3 mg 1-'h),
with a group mean (s.d.) of 348.8 ± 136.4 mg 1-l h. With the addi-
tion ofCSA, the VM26 AUC ranged from 194.2 to 1055.1 mg 1-lh
(median 432.9 mg 1-' h),with a group mean (s.d.) of514.4 ± 213.4
mg-' l.h. There was, however, a significant interpatient variation
in the alteration of VM26 AUC, with increases ranging from
-20% to about 100%). No significant correlation was found
between the AUC of CSA and the variation in VM26 AUC
(Figure 1).
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Table 2 Kinetic parameters of VM26 administered alone and together with CSA
Cmax (mg 1-1) AUC (mg I-t h) V(l r-2) t1,2(h) CI(l h-' m-2)
VM26
Mean ± s.d. 12.7 ± 3.4 348.8 ± 136.4 6.8 ± 1.2 7.2 ± 2.8 0.64 ± 0.2
Median (range) 10.9 (7.0-22.3) 290.3 (168.4-791.0) 5.5 (4.4-9.0) 6.8(2.8-14.8) 0.62 (0.25-1.2)
VM26 + CSA
Mean ±s.d. 16.0 ±4.6 514.4 ± 213.4 6.5±1.8 11.2 ±4.4 0.46± 0.21
Median (range) 14.3 (8.0-23.1) 432.9 (194.2-1055.1) 5.9 (4.8-11.6) 9.1 (3.7-22.3) 0.45 (0.2-1.03)
Fold increasea 1.28 ± 0.27 1.50 ± 0.41 1.12 ± 0.41 1.72 ± 1.04 0.73 ± 0.24
P2 <0.01 <0.01 NS <0.01 <0.01
aRatio (mean ± s.d.) of paired kinetic parameters after and before CSA. bpby the paired t-test.
Table 3 Comparison of total and renal clearance of VM26 in seven patients
who received VM26 alone and VM26 plus CSA
Parameter VM26 VM26 plus CSA Decrease (%) P
Total Cl 0.67±0.14 0.53±0.25 21 < 0.05b
(I h-1 m-2)
Renal Cla 0.038±0.022 0.022±0.019 59 <0.05
(I h-1 m-2)
aRenal clearance (C/r) was calculated by the formula Cl, = total clearance x
fraction excreted in the urine (fu) Fu was 5.6±3.9% and 4.0±1.8% in the
courses of VM26 alone and VM26 plus CSA respectively. bSignificant
differences in VM26 clearance in the presence and absence of CSA by the
paired t-test.
The kinetic parameters ofVM26 administered alone or together
with CSA are reported and compared in Table 2. Terminal half-life
(t1,2f) of VM26 was significantly (P<0.01) increased (1.72-fold)
when CSA was added to the antineoplastic drug, whereas the
systemic clearance of VM26 (CI-VM26) was decreased by 1.4-
fold (P<O.01). Cmax of VM26 increased overall by 1.28-fold after
addition of CSA (P<0.01). No significant (P = NS) differences
were observed in the apparent volume ofdistribution (V-VM26) in
the presence or absence ofCSA.
Seven patients had adequate urine collections to evaluate
whether the decrease in total VM26 renal clearance during CSA
administration was attributable to renal or non-renal clearance
mechanisms, or both. The CSA plus VM26 regimen produced a
59% decrease in renal clearance (Table 3), whereas total clearance
of VM26 was decreased by only 21% after CSA administration.
However, in the patients treated with VM26 alone and with VM26
plus CSA, only a fraction (< 6%) of total clearance resulted from
renal clearance.
Treatment response and toxicity
All 16 patients that entered the study crossed over to receive CSA.
At the time ofcross-over, nine patients had received two courses of
VM26 alone. Among these, six had progressive disease and three
had stable disease. Since no response was observed after two
courses ofVM26 alone,theremaining sevenpatients crossed overto
VM26 plus CSA after only one course of VM26. The total number
of courses of VM26 plus CSA was 42 (median number 2; range
2-5). All courses were administered according to the treatment
protocol and, in one patient, the dose ofVM26 was reduced to 75%
afterthe firstcycle with VM26 andCSA because ofG4 neutropenia.
To compare the response and toxicity profile of VM26 with and
without CSA, patients were evaluated after the first or second
course of VM26 alone and after the second course of VM26 plus
CSA. However, evaluations performed after the second course of
VM26 plus CSA suggested that toxicity was not cumulative, as
previously reported (Warner et al, 1995). Fifteen patients were
evaluable for toxicity (one patient did not undergo the scheduled
tests because ofrapidly progressive disease).
After treatment with VM26 alone, all patients had hair loss,
three had grade 3 neutropenia (two of them with fever) and one
patient had a cutaneous eruption treated with corticosteroids.
Gastrointestinal toxicity was mild, with <15% ofcycles associated
with significant vomiting, mucositis or constipation.
The addition ofCSA was clearly associated with increased toxi-
city. Prolonged sensation of heat occurred in seven patients. This
side-effect could be ascribed to the cremophor contained in the
preparation of CSA, as previously suggested by Rodenburg et al
(1991). Epigastric pain occurred in three patients and in one case it
determined an early interruption of CSA infusion. All these side-
effects were caused by CSA rather than VM26. They disappeared
at the end ofCSA infusion, only to recur when CSA was restarted
on the subsequent course.
Other side-effects observed after VM26 and CSA were grade 2
mucositis (one patient) and threefold n.v. AST elevation (one
patient). Total bilirubin was increased after VM26 plus CSA
compared with VM26 alone (P<0.01). In the patients treated with
VM26 plus CSA, the mean value ofbilirubin was 3.1 ± 0.8 mg 100
ml-' (median of 2.5 mg 100 ml-'; range 1.2-6.5 mg 100 ml-'),
whereas in the patients treated with VM26 alone, bilirubin was in
the normal range (<1.5 mg 100 ml-').Hyperbilirubinaemia owing to
CSA was rapidly reversible after the completion ofCSA infusion.
Haematological toxicity was more pronounced after the addi-
tion of CSA to VM26. The individual values of nadir neutrophil
count (ANC) were decreased after VM26 plus CSA compared
with VM26 alone [P< 0.01; median ANC was 700 ,l-l (range <
100-2860pl-1) and 1900 pl-l (range 200-6000 1-1') respectively].
Two patients were hospitalized because offebrile neutropenia and
treated with i.v. antibiotics and granulocyte colony-stimulating
factor (G-CSF) with complete resolution. Thrombocytopenia with
platelet counts less than 50 000 ul-l occurred in one patient treated
with VM26 and CSA. A significant correlation (r = -0.51, P <
0.05) between the nadir of ANC and VM26 AUC was found both
in the patients treated with VM26 alone and in those treated with
VM26 plus CSA (r = -0.61, P = 0.01) (Figure 2). However, the
nadir values of ANC standardized for AUC of VM26 (i.e.
ANC/AUC ratio) were significantly (P < 0.01) higher in the
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patients treated with VM26 alone than in those treated with VM26
plus CSA (Figure 2), suggesting that factors other than the AUC of
VM26 could contribute to the neutropenia. ANC/AUC ratio was
7.38 ± 5.51 and 2.43 ± 2.68 in patients treated with VM26 alone
and VM26 plus CSA respectively (P<0.01 by the paired t-test).
No objective response was documented in the 15 evaluable
patients (one patient showing no change died of cardiac arrest in
another hospital 5 weeks after the beginning of treatment with
VM26 and CSA): six patients had progressive disease and nine
patients had stabilization with a median duration of 4 months
(range 2-14 months). One patient ofunchanged group had a minor
response on the lung parameter (and a grade 4 haematological
toxicity). Follow-up was performed for at least 20 months.
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CSA has proved to be a highly effective modulator of MDR in
vitro (Osieka et al, 1986; Meador et al, 1987; Meador et al, 1987;
Twentyman, 1992). On the basis of these promising experimental
data, many clinical trials have been performed, but the results have
been generally disappointing. CSA restores chemosensitivity only
in a limited subset of tumours expressing P-gp and having rapid
~growth kinetics, such as haematological malignancies (Sonneveld
and Nooter, 1990; Sonneveld et al, 1992). Conversely, no previous
clinical trials have demonstrated that P-gp inhibition by CSA or
other chemosensitizers improves the clinical outcome of
~~~chemotherapy in slowly proliferating cancers with the MDR
phenotype (Verweij et al, 1991), such as RCC (Rodenburg et al,
1991; Warner et al, 1995). This raises the question of whether inhi-
bition of P-gp activity is crucial to increase the cytotoxic effects of
the antineoplastic drugs and to improve clinical outcome.
The dosage of CSA we used in this study allowed us to obtain
CSA plasma levels ranging from 1830 ng ml'to 4501 ng ml-'.
Many studies performed in in vitro experimental models
(Sonneveld and Nooter, 1990; Verweij et al, 1991; Twentyman,
1992) have demonstrated that this range was effective in inhibiting
P-gp. Conversely, the plasma levels of the CSA metabolites we
investigated were in the range that previous studies (Charuk et al,
1995) and our unpublished results showed not to be effective in
reverting P-gp activity. Despite the relatively effective CSA level
we obtained, only a minor response was observed in 16 RCC
patients treated with VM26 and CSA. Moreover, a comparison of
the haemopoietic toxicity in the cycles with VM26 alone and in
those with VM26 plus CSA showed increased neutrophil toxicity
in the latter, in accordance with other studies reporting an
increased haematological toxicity after administration of MDR-
related drugs with CSA (Yahanda et al, 1992; Warner et al, 1995).
In clinical trials using a P-gp-modulating agent with chemo-
therapy, if enhanced toxicity occurs after addition of the modulator
to the chemotherapy, this could result either from increased plasma
concentration of the cytotoxic agents secondary to a pharmacoki-
netic interaction or from the inhibition of P-gp activity in normal
cells. Previous studies have reported that CSA increases the AUC
of many antineoplastic drugs, including doxorubicin and etoposide
(Lum et al, 1992), but no data on the effect of CSA on VM26 phar-
macokinetics have been reported. In the present trial, patients
ts treated with served as their own controls so that the effect of the addition of
if correlation) CSA on VM26 pharmacokinetics was clearly established. We
lent correlation found that CSA significantly (P<0.01) increased the AUC of
ad with VM26
VM26, and a significant association was observed between VM26
AUC and absolute neutrophil count (ANC). At present the precise
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mechanism responsible for the increased AUC after CSA adminis-
tration is not clearly defined. Previous studies suggested that inhi-
bition of the activity of P-gp expressed in biliary canaliculi and
proximal renal tubuli could increase the AUC of antineoplastic
drugs by reducing their clearance from the plasma (Lum et al,
1992). P-gp could have a potential function in the excretion of
antineoplastic drugs or other substrates, such as bilirubin, into both
bile and urine (Gosland et al, 1991), and we observed a significant
increase in the plasma level ofbilirubinaemia after CSA exposure.
However, we think that modulation of P-gp activity by CSA in
biliary canaliculi and in proximal renal tubules cannot completely
explain the increase in AUC concentration of VM26 after CSA
administration. Renal and biliary excretion of VM26, in fact,
represents a small part of the total elimination of the drug (Clark
and Slevin, 1987). In accordance with these data, we found that
CSA affected the renal clearance of VM26, but only a fraction
(< 6%) of total clearance was caused by renal clearance. We think
that the increase in the AUC of VM26 could be related to an
altered metabolism of the drug. Recently, Relling et al (1994)
reported that CSA could interfere with the O-demethylation of
VM26 mediated by cytochrome P450 3A4. CSA is a substrate for
this cytochrome and inhibits catechol formation from VM26.
Comparison of VM26 AUC in the cycles with VM26 alone
and in those with VM26 plus CSA suggests that mechanisms
other than the increase in the VM26 AUC could contribute to
neutropenia. In fact, similar VM26 AUC determined a greater
reduction in the ANC of patients treated with CSA than in that
of patients not exposed to the modulating agent. It must be
considered that haemopoietic precursor cells overexpress P-gp
(Chaudhary and Roninson, 1991; Klimecki et al, 1994). Therefore,
inhibition of P-gp activity could increase the cytotoxic effect of
VM26 on these cells, in addition to the neutropenic effect of
VM26 AUC.
Even if many explanations could be proposed to account for the
different cytotoxic effects resulting from the reversal treatment in
the RCC and in haemopoietic cells (i.e. otherresistant mechanisms
could be involved, or the level of CSA at the target site could not
be adequately sensitizing), it is worth considering that RCCs are
tumours with slower growth kinetics than haemopoietic precursors
(Vincent, 1983). Therefore, inhibition of P-gp activity could result
in a chemosensitizing effect on MDR cells with rapid growth
kinetics, but not in MDR cells with longer doubling times. We
demonstrated previously that similar increases in the intracellular
DOX content owing to P-gp inhibition (Toffoli et al, 1996) deter-
mined a greater enhancement of the cytotoxic activity of the anti-
neoplastic drug in fast-cycling cells compared with slow-cycling
cells. It is well known that cell chemosensitivity towards many
antineoplastic drugs is a function of the cellular replication
kinetics and, very probably, of the specific biochemical functions
that cells express in a cell cycle-coordinate fashion. VM26 inter-
acts primarily with topoisomerase II, an enzyme whose expression
reaches the highest levels in the S-G2M phase of the cell cycle
(Kimura et al, 1994). Fast-cycling cells have a higher fraction of
cells in this phase and, therefore, are more affected by drug cyto-
toxicity than slow-cycling cells.
CSA at the dosage we used in the patients probably overcomes
drug resistance mediated by P-gp, but inhibition of P-gp activity
increases the cytotoxic effect of the antineoplastic drug only in
MDR cells in which unresponsivity to the antineoplastic treatment
is principally caused by an unpaired intracellular drug accumula-
tion. This could be the case in MDR cells with rapid growth
kinetics, such as haemopoietic precursor cells, which are virtually
chemosensitive to antineoplastic drugs. Conversely, reversal treat-
ment had no effect on MDR cells with longer doubling times (i.e.
RCC), since in these cells the growth kinetic characteristics or
other drug-resistant mechanisms not related to P-gp expression,
are the major impediment to the efficacy of an antineoplastic drug
treatment.
In conclusion, this study demonstrates that CSA affects both the
pharmacokinetics and the pharmacodynamics of VM26 in patients
with RCC. In tumours with slow growth kinetics, such as RCCs,
inhibition of P-gp activity is probably necessary but not sufficient
to restore the chemosensitivity to the antineoplastic drugs. In these
tumours, new modalities of treatment must be adopted to improve
clinical results.
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